Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 34
Filter
1.
Rev. méd. Chile ; 146(7): 839-845, jul. 2018. tab
Article in Spanish | LILACS | ID: biblio-961469

ABSTRACT

Background: Bacteremic pneumococcal pneumonia (BPP) is a preventable disease with high morbimortality. Aim: To evaluate clinical aspects and mortality on BPP patients admitted to a Chilean regional hospital. Patients and Methods: We looked for adult patients with Streptococcus pneumoniae isolated from blood cultures between 2010 and 2014 years and reviewed clinical records of those who were admitted with pneumonia. Results: We identified 70 BPP patients: 58% were men, mean age was 56 years, 30% were > 65 years, 70% with basic public health insurance, 26% were alcoholics, 86% had comorbidities. Only two patients were vaccinated against S. pneumoniae. CURB-65 severity index for community acquired pneumonia was > 3 in 37% of patients. Twenty-four patients were admitted to ICU, twenty required mechanical ventilation and twenty-four died (34%). Mortality was associated with an age over 65 years, presence of comorbidities and complications of pneumonia. A total of 22 serotypes of S. pneumoniae were identified, five of them (1,3,7F,14 y 9V) were present in 57% of cases. Conclusions: Elevated mortality of our BNN patients was associated with comorbidities and possibly with socio economic factors, which conditioned a late access to medical care.


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Pneumonia, Pneumococcal/mortality , Bacteremia/mortality , Pneumonia, Pneumococcal/diagnosis , Pneumonia, Pneumococcal/microbiology , Pneumonia, Pneumococcal/drug therapy , Socioeconomic Factors , Streptococcus pneumoniae/isolation & purification , Severity of Illness Index , Ceftriaxone/therapeutic use , Comorbidity , Chile/epidemiology , Risk Factors , Hospital Mortality , Bacteremia/microbiology , Bacteremia/drug therapy , Community-Acquired Infections/microbiology , Community-Acquired Infections/mortality , Community-Acquired Infections/drug therapy , Anti-Bacterial Agents/therapeutic use
2.
Rev. chil. cardiol ; 37(1): 38-41, abr. 2018. ilus
Article in Spanish | LILACS | ID: biblio-959337

ABSTRACT

Resumen: El Síndrome de Austrian, corresponde al cuadro clínico descrito por Robert Austrian en 1957, definido por la triada de Neumonía, Endocarditis Infecciosa (EI) y Meningitis, causado por Streptococcus pneumoniae. En la mayoría de los casos el vicio valvular presente, es la insuficiencia valvular aórtica, cuyo tratamiento médico y resolución quirúrgica de acuerdo con su gravedad, deben ser realizados precoz y oportunamente. Un paciente de 51 años, sin antecedentes de valvulopatía, con historia de poli consumo de alcohol y cocaína comenzó dos semanas previo a su ingreso hospitalario con síndrome febril, neumonía, y meningitis bacteriana por Streptococcus pneumoniae. Sus hemocultivos fueron negativos. El ecocardiograma transesofágico (ETE) fue compatible con EI valvular aórtica con insuficiencia moderada a severa. Se trató como EI a microorganismo desconocido y se efectuó un reemplazo valvular aórtico electivo con prótesis biológica a la 5° semana después de terminado el tratamiento médico antibiótico, cuyo resultado fue exitoso.


Abstract: A syndrome including Infective endocarditis, pneumonia and Meningitis caused by S pneumoniae was described by Robert Austrian in 1957. The aortic valve is affected in most cases. Medical followed by surgical treatment should be promptly implemented. The clinical case of a 51 year old man with a history of multiple drug consumption developing fever, pneumonia, and meningitis caused by S pneumoniae is presented. Blood cultures were negative and trans esophageal echocardiography showed aortic valve vegetations and moderate regurgitation. After multiple antibiotic treatment the patient underwent aortic valve replacement and recovered satisfactorily. Clinical and epidemiological characteristics of this syndrome are discussed.


Subject(s)
Humans , Male , Middle Aged , Pneumonia, Pneumococcal/surgery , Endocarditis, Bacterial/surgery , Meningitis, Pneumococcal/surgery , Pneumonia, Pneumococcal/diagnosis , Pneumonia, Pneumococcal/drug therapy , Streptococcus pneumoniae , Syndrome , Echocardiography, Transesophageal , Endocarditis, Bacterial/diagnosis , Endocarditis, Bacterial/drug therapy , Meningitis, Pneumococcal/diagnosis , Meningitis, Pneumococcal/drug therapy , Anti-Bacterial Agents/therapeutic use
3.
Medicina (B.Aires) ; 75(4): 245-257, Aug. 2015. tab
Article in Spanish | LILACS | ID: biblio-841505

ABSTRACT

La neumonía adquirida en la comunidad (NAC) en adultos es causa frecuente de morbilidad y mortalidad, especialmente en adultos mayores y en sujetos con comorbilidades previas. La mayoría de los episodios son de etiología bacteriana, Streptococcus pneumoniae es el patógeno aislado con mayor frecuencia. La vigilancia epidemiológica permite conocer los cambios en los microorganismos productores y su sensibilidad a los antimicrobianos; recientemente se ha observado un incremento en aislamientos de Staphylococcus aureus resistente a la meticilina y Legionella sp. La radiografía de tórax resulta imprescindible como herramienta diagnóstica. El score CURB-65 y la oximetría de pulso permiten estratificar a los pacientes en aquellos que requieren manejo ambulatorio, hospitalización en sala general o unidad de terapia intensiva. Los estudios diagnósticos y el tratamiento antimicrobiano empírico también se basan en esta estratificación. Los biomarcadores tales como procalcitonina o proteína-C reactiva no son parte de la evaluación inicial dado que su utilización no demostró modificar el manejo de los episodios de NAC. El tratamiento antibiótico sugerido para pacientes ambulatorios menores de 65 años sin comorbilidades es amoxicilina; pacientes ≥ 65 años o con comorbilidades: amoxicilina-clavulánico/sulbactam; hospitalizados en sala general: ampicilina sulbactam con o sin claritromicina; pacientes admitidos a unidad de terapia intensiva: ampicilina-sulbactam más claritromicina. La duración del tratamiento es de 5 a 7 días para tratamiento ambulatorio y 7 a 10 para los hospitalizados. En época de circulación del virus de la influenza se sugiere el agregado de oseltamivir para los pacientes hospitalizados y para aquellos con comorbilidades.


Community-acquired pneumonia in adults is a common cause of morbidity and mortality particularly in the elderly and in patients with comorbidities. Most episodes are of bacterial origin, Streptococcus pneumoniae is the most frequently isolated pathogen. Epidemiological surveillance provides information about changes in microorganisms and their susceptibility. In recent years there has been an increase in cases caused by community-acquired meticillin resistant Staphylococcus aureus and Legionella sp. The chest radiograph is essential as a diagnostic tool. CURB-65 score and pulse oximetry allow stratifying patients into those who require outpatient care, general hospital room or admission to intensive care unit. Diagnostic studies and empirical antimicrobial therapy are also based on this stratification. The use of biomarkers such as procalcitonin or C-reactive protein is not part of the initial evaluation because its use has not been shown to modify the initial approach. We recommend treatment with amoxicillin for outpatients under 65 year old and without comorbidities, for patients 65 years or more or with comorbidities amoxicillin-clavulanic/sulbactam, for patients hospitalized in general ward ampicillin-sulbactam with or without the addition of clarithromycin, and for patients admitted to intensive care unit ampicillin-sulbactam plus clarithromycin. Suggested treatment duration is 5 to 7 days for outpatients and 7 to 10 for those who are hospitalized. During the influenza season addition of oseltamivir for hospitalized patients and for those with comorbidities is suggested.


Subject(s)
Humans , Adult , Middle Aged , Aged , Pneumonia, Pneumococcal/diagnosis , Pneumonia, Pneumococcal/microbiology , Pneumonia, Pneumococcal/drug therapy , Pneumonia, Pneumococcal/epidemiology , Streptococcus pneumoniae , Community-Acquired Infections/diagnosis , Community-Acquired Infections/microbiology , Community-Acquired Infections/drug therapy , Community-Acquired Infections/epidemiology , Anti-Bacterial Agents/therapeutic use
4.
Rev. méd. Chile ; 143(5): 553-561, tab
Article in Spanish | LILACS | ID: lil-751699

ABSTRACT

Background: The clinical usefulness of blood cultures in the management of patients hospitalized with community-acquired pneumonia (CAP) is controversial. Aim: To determine clinical predictors of bacteremia in a cohort of adult patients hospitalized for community-acquired pneumonia. Material and Methods: A prospective cohort of 605 immunocompetent adult patients aged 16 to 101 years (54% male) hospitalized for CAP was studied. The clinical and laboratory variables measured at admission were associated with the risk of bacteremia by univariate and multivariate analysis using logistic regression models. Results: Seventy seven percent of patients had comorbidities, median hospital stay was 9 days, 7.6% died in hospital and 10.7% at 30 days. The yield of the blood cultures was 12.6% (S. pneumoniae in 69 patients, H. influenzae in 3, Gram negative bacteria in three and S. aureus in one). These results modified the initial antimicrobial treatment in one case (0.2%). In a multivariate analysis, clinical and laboratory variables associated with increased risk of bacteremia were low diastolic blood pressure (Odds ratio (OR): 1.85, 95% confidence intervals (CI) 1.02 to 3.36, p < 0.05), leukocytosis e" 15,000/mm³ (OR: 2.18, 95% CI 1.22 to 3.88, p < 0.009), serum urea nitrogen e" 30 mg/dL (OR: 2.23, 95% CI 1.22 to 4.05, p < 0.009) and serum C-reactive protein e" 30 mg/dL (OR: 2.20, 95% CI 1.22 to 3.97, p < 0.01). Antimicrobial use before hospital admission significantly decreased the blood culture yield (OR: 0.14, 95% CI 0.04 to 0.46, p < 0.002). Conclusions: Blood cultures do not contribute significantly to the initial management of patients hospitalized for community-acquired pneumonia. The main clinical predictors of bacteremia were antibiotic use, hypotension, renal dysfunction and systemic inflammation.


Subject(s)
Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Young Adult , Bacteremia/diagnosis , Pneumonia, Bacterial/diagnosis , Analysis of Variance , Anti-Bacterial Agents/therapeutic use , Bacteremia/complications , Bacteremia/drug therapy , Bacteremia/microbiology , Cardiovascular Diseases/complications , Community-Acquired Infections/complications , Community-Acquired Infections/diagnosis , Community-Acquired Infections/drug therapy , Hospitalization/statistics & numerical data , Hypotension/complications , Length of Stay/statistics & numerical data , Microbial Sensitivity Tests , Pneumonia, Bacterial/complications , Pneumonia, Bacterial/drug therapy , Pneumonia, Pneumococcal/complications , Pneumonia, Pneumococcal/diagnosis , Pneumonia, Pneumococcal/drug therapy , Pneumonia, Pneumococcal/microbiology , Prognosis , Prospective Studies , Renal Insufficiency/complications , Streptococcus pneumoniae/isolation & purification
5.
Neumol. pediátr ; 8(2): 86-90, 2013. graf
Article in Spanish | LILACS | ID: lil-701694

ABSTRACT

Streptococcus pneumoniae is the most common bacterial cause of pneumonia in children and has become a topic of controversy for epidemiological changes that have been seen in recent years with the advent of the vaccine and the emergence of serotypes that cause increased morbidity which were not covered by the heptavalent vaccine. Also there have been changes in the concepts of resistance in recent years. This has led to the reevaluation of the use of specific antibiotics for management.


El Streptococcus pneumoniae es la causa bacteriana más frecuente de neumonía en los niños y se ha convertido en un tema de controversia por los cambios epidemiológicos que se han visto en los últimos años con el advenimiento de la vacuna y el surgimiento de serotipos que causan mayor morbilidad que no estaban cubiertos por la vacuna heptavalente. Igualmente se han presentado cambios en los conceptos de resistencia en los últimos años. Esto ha motivado la reevaluación del uso de los antibióticos específicos para su manejo.


Subject(s)
Humans , Child , Drug Resistance, Microbial , Pneumonia, Pneumococcal/drug therapy , Anti-Bacterial Agents/therapeutic use , Colombia , Global Health , Pneumonia, Pneumococcal/epidemiology , Penicillin Resistance , Streptococcus pneumoniae
6.
J. pediatr. (Rio J.) ; 87(1): 70-75, jan.-fev. 2011. graf, tab
Article in Portuguese | LILACS | ID: lil-576132

ABSTRACT

OBJETIVOS: Identificar os sorotipos de pneumococo mais frequentemente isolados de crianças internadas com pneumonia invasiva, comparar os sorotipos com os incluídos em vacinas conjugadas e analisar sua sensibilidade aos antimicrobianos mais utilizados na faixa etária pediátrica. MÉTODOS: Estudo descritivo, retrospectivo das pneumonias pneumocócicas identificadas em crianças internadas no hospital universitário da Universidade de São Paulo, no período de janeiro de 2003 a outubro de 2008. Os critérios de inclusão foram: faixa etária de 29 dias até 15 anos incompletos com diagnóstico clínico e radiológico de pneumonia e com cultura de sangue e/ou líquido pleural com crescimento de Streptococcus pneumoniae. RESULTADOS: Foram incluídas no estudo 107 crianças. Os sorotipos mais frequentes foram: 14 (36,5 por cento), 1 (16,7 por cento), 5 (14,6 por cento), 6B (6,3 por cento) e 3 (4,2 por cento). A proporção de sorotipos contidos na vacina conjugada heptavalente seria de 53,1 por cento, na vacina 10-valente de 86,5 por cento e na 13-valente seria de 96,9 por cento. De acordo com os padrões do Clinical and Laboratory Standards Institute 2008, 100 cepas (93,5 por cento) de pneumococos foram sensíveis à penicilina (concentração inibitória mínima, CIM < 2 µg/mL), 7 cepas (6,5 por cento) com resistência intermediária (CIM = 4 µg/mL) e nenhuma com resistência (CIM > 8 µg/mL). Verificamos alta taxa de sensibilidade para as cepas testadas para vancomicina, rifampicina, ceftriaxone, clindamicina, cloranfenicol e eritromicina. CONCLUSÕES: Nossos resultados confirmam um expressivo impacto potencial das vacinas conjugadas, principalmente pela 10-valente e 13-valente, sobre os casos de pneumonias invasivas. Os resultados de sensibilidade à penicilina evidenciam que a opção terapêutica de escolha para o tratamento das pneumonias invasivas continua sendo a penicilina.


OBJECTIVES: To identify the most common pneumococcal serotypes in children hospitalized with invasive pneumonia, correlate isolated serotypes with those included in conjugate vaccines, and ascertain the sensitivity of the isolated pneumococcal strains to penicillin and other antibiotics. METHODS: From January 2003 to October 2008, a retrospective study of hospitalized children with a diagnosis of Streptococcus pneumoniae pneumonia was conducted at the university hospital of Universidade de São Paulo. Criteria for inclusion were: age greater than 29 days and less than 15 years, radiological and clinical diagnosis of pneumonia, and isolation of Streptococcus pneumoniae in blood cultures and/or pleural effusion. RESULTS: The study included 107 children. The most common serotypes were 14 (36.5 percent), 1 (16 percent), 5 (14.6 percent), 6B (6.3 percent) and 3 (4.2 percent). The proportion of identified serotypes contained in the heptavalent, 10-valent and 13-valent conjugate vaccines was 53.1, 86.5, and 96.9 percent, respectively. Pneumococcal strains were sensitive to penicillin (minimum inhibitory concentration, MIC < 2 µg/mL) in 100 cases (93.5 percent) and displayed intermediate resistance (MIC = 4 µg/mL) in 7 cases (6.5 percent). No strains were penicillin-resistant (MIC > 8 µg/mL) according to the Clinical and Laboratory Standards Institute 2008 standards. Tested isolates were highly sensitive to vancomycin, rifampicin, ceftriaxone, clindamycin, erythromycin, and chloramphenicol. CONCLUSIONS: Our results confirm a significant potential impact of conjugate vaccines, mainly 10-valent and 13-valent, on invasive pneumonia. Furthermore, susceptibility testing results show that penicillin is still the treatment of choice for invasive pneumonia in our setting.


Subject(s)
Adolescent , Child , Child, Preschool , Humans , Infant , Infant, Newborn , Anti-Bacterial Agents/pharmacology , Pneumonia, Pneumococcal/microbiology , Streptococcus pneumoniae/genetics , Brazil , Hospitals, University , Microbial Sensitivity Tests , Penicillins/pharmacology , Pneumococcal Vaccines/immunology , Pneumonia, Pneumococcal/drug therapy , Pneumonia, Pneumococcal/immunology , Retrospective Studies , Serotyping , Streptococcus pneumoniae/drug effects , Streptococcus pneumoniae/immunology
9.
Rev. chil. infectol ; 26(1): 9-17, feb. 2009. ilus, tab
Article in Spanish | LILACS | ID: lil-508608

ABSTRACT

We evaluated the utility of blood cultures in the therapeutic management of patients with bacteremic pneumococcal pneumonia admitted to an internal medicine unit, in a retrospective observational study. Forty-nine patients were included, 75.5 percent were men, mean age 51.1 years. All S. pneumoniae strains were susceptible to penicillin. Four patients died. In 15.5 percent the treatment was modified narrowing antibiotic spectrum, in 51 percent cases it was changed to bencylpenicillin or amoxicillin exclusively, but only in 16 percent within the first 4 days. In 12 cases the prescription coincided with the oral switch therapy to amoxicillin. Due to the benefits and potential advantages of penicillin in diminishing the incidence of antibiotic resistance and reducing costs, it is important to work on prescription habits among physicians. This is especially important in the case of penicillin and the opportune moment of therapy change, improving the use of the microbiological report.


Evaluamos la utilidad de los hemocultivos en el manejo terapéutico de pacientes con neumonía neumocóccica bacteriémica internados en un servicio de clínica médica. Estudio observacional, retrospectivo. Se incluyeron 49 pacientes, 75,5 por ciento hombres, edad media 51,1 años. Todas las cepas de S. pneumoniae fueron susceptibles a penicilina. Fallecieron 4 pacientes. En 75,5 por ciento) se modificó el tratamiento con reducción del espectro antibacteriano, en 57 por ciento se cambió a bencilpenicilina o amoxicilina como único antimicrobiano, pero sólo en 16 por ciento se realizó dentro de los primeros cuatro días. En 12 casos la indicación coincidió con el cambio a vía oral por amoxicilina. Debido a los beneficios y ventajas potenciales de penicilina en mejorar el problema de la resistencia antimicrobiana, y en algunos casos reducir los costos, es importante trabajar sobre las prácticas de prescripción de los médicos clínicos, acerca de la indicación de penicilina y al momento oportuno del cambio, mejorando la utilización del informe microbiológico.


Subject(s)
Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Bacteremia/microbiology , Pneumonia, Pneumococcal/microbiology , Anti-Bacterial Agents/therapeutic use , Bacteremia/drug therapy , Culture Media , Microbial Sensitivity Tests , Pneumonia, Pneumococcal/drug therapy , Retrospective Studies , Serotyping , Severity of Illness Index , Streptococcus pneumoniae/classification , Streptococcus pneumoniae/drug effects , Streptococcus pneumoniae/isolation & purification
10.
Korean Journal of Radiology ; : 531-534, 2009.
Article in English | WPRIM | ID: wpr-225677

ABSTRACT

Novel influenza A (H1N1) virus is the pathogen of recent global outbreaks of febrile respiratory infection. We herein report the imaging findings of pulmonary complication in two patients with novel influenza A (H1N1) infection. The first patient without secondary infection showed the ill-defined ground-glass opacity nodules and patch areas of ground-glass opacities. The second patient with secondary pneumococcal pneumonia showed areas of lobar consolidation in the right middle lobe and left lower lobe and ground-glass opacities.


Subject(s)
Adolescent , Adult , Female , Humans , Influenza A Virus, H1N1 Subtype , Influenza, Human/complications , Lung/diagnostic imaging , Pneumonia, Pneumococcal/drug therapy , Radiography, Thoracic , Reverse Transcriptase Polymerase Chain Reaction , Tomography, X-Ray Computed
11.
Southeast Asian J Trop Med Public Health ; 2008 May; 39(3): 461-6
Article in English | IMSEAR | ID: sea-31827

ABSTRACT

A total of 400 clinical Streptococcus pneumoniae strains from patients with respiratory diseases were collected from January 2002 to December 2005. In this study, an increased prevalence of penicillin-nonsusceptible S. pneumoniae (PNSP) from 63% in 2002-2003 to 69% in 2004-2005 was found. During 2004-2005, 56% were erythromycin-nonsusceptible S. pneumoniae (ENSP) and 54% were both PNSP and ENSP. The PNSP, ENSP and PNSP+ENSP groups showed similar trends, ie, sensitive to amoxicillin/clavulanate (range 97.2-98.5%), levofloxacin (range 90.7-92.4%), ceftriaxone (range 87.1-89.4%), and ofloxacin (range 64.8-66.1%). Lower levels of susceptibility were detected for azithromycin, clarithromycin, cefdinir, cefprozil, clindamycin, co-trimoxazole, chloramphenicol and tetracycline in penicillin and erythromycin-nonsusceptible strains. Of the macrolide-resistant S. pneumoniae, 55% of strains exhibited the M phenotype and 45% the constitutive MLS(B) phenotype. No pneumococci with the inducible MLS(B) phenotype were detected in Thailand.


Subject(s)
Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Community-Acquired Infections/drug therapy , Drug Resistance, Multiple, Bacterial , Female , Humans , Infant , Male , Microbial Sensitivity Tests , Middle Aged , Penicillin Resistance , Penicillins/therapeutic use , Pneumonia, Pneumococcal/drug therapy , Respiratory System/microbiology , Streptococcus pneumoniae/drug effects , Thailand/epidemiology
12.
Rev. chil. infectol ; 24(4): 264-269, ago. 2007. tab
Article in Spanish | LILACS | ID: lil-459589

ABSTRACT

The increasing reporting of Streptococcus pneumoniae resistance to penicillin has lead to the recommendation of third generation cephalospirins for the treatment of serious pneumococcal infections. As a consequence, clinicians usually do not prescribe first line antibiotics despiste the availability of susceptibility studies. Whit the aim to evaluate the impact of the infectious diseases specialist evaluation in the apropriate use oh the susceptibility studies, two series were compared: a historic control one (1998-2002, n = 50) and a prospectuve group that had the advisement of one infectious diseases specialist (2003-2006, n = 60). In both series, pneumonia stood out as the source of the bacteremia, and -alcoholism/hepatic insufficiency as associated factor. In the first series, 48 isolates resulted susceptible to penicillin by agar diffusion, and 1 out of 36 patients with pneumonia had a change in the antibiotic therapy to penicillin. In the prospective series, we found 56 susceptible isolates, and the remaining four were classified as intermediate susceptibility according to the MIC value. Antibiotics were changed in 36 out of 50 patients with bacteremic pneumococcal pneumonia (p < 0.05). The infectious diseases specialist evaluation had a positive impact on the use of the microbiological information for therapeutics purposes.


La descripción creciente de Streptococcus pneu-moniae resistente a penicilina, ha llevado a la recomendación de emplear cefalosporinas de tercera generación para el tratamiento de las infecciones neumo-cócicas graves. Como consecuencia, los médicos clínicos no prescriben, usualmente, antimicrobianos de primera línea, a pesar de disponer de estudios de susceptibilidad in vitro. Con el propósito de evaluar el impacto de la asesoría del infectólogo para el uso adecuado de los estudios de susceptibilidad, se compararon dos series: un control histórico (1998-2002, n = 50) y un grupo prospectivo en que sí hubo asesoría infectológica (2003-2006, n = 60). En ambas series, la neumonía fue el foco principal de bacteriemia y alcoholismo/falla hepática los factores asociados más frecuentes. En el primer grupo, 48 aislados resultaron susceptibles a penicilina por prueba de difusión en agar y en uno de 36 pacientes con neumonía, se efectuó cambio en la terapia antimicrobiana a bencilpeni-cilina. En el grupo prospectivo, hubo 56 cepas susceptibles y las cuatro restantes fueron clasificadas como de susceptibilidad intermedia, de acuerdo con los valores de CIM. Se cambió de antimicrobiano en 36 de 50 pacientes con neumonía neumocóccica bacteriémica (p < 0,05). La evaluación hecha por el infectólogo tuvo un impacto positivo en el uso de información micro-biológica con fines terapéuticos.


Subject(s)
Adult , Female , Humans , Male , Middle Aged , Anti-Bacterial Agents/therapeutic use , Bacteremia/drug therapy , Pneumonia, Pneumococcal/drug therapy , Streptococcus pneumoniae/drug effects , Bacteremia/microbiology , Case-Control Studies , Microbial Sensitivity Tests , Penicillin Resistance , Prospective Studies
13.
Indian J Pediatr ; 2006 Apr; 73(4): 305-9
Article in English | IMSEAR | ID: sea-79990

ABSTRACT

OBJECTIVE: To compare the efficacy of sequential injectable crystalline penicillin (C.pen) and gentamicin combination followed by oral amoxicillin with sequential IV and oral amoxicillin-clavulanate (amox-clav) in treatment of severe or very severe hypoxemic pneumonia. METHODS: Children aged 2-59 months with WHO-defined severe or very severe pneumonia with hypoxemia (SpO2 < 90%) were included in the study. Patients with fever > 10 days, bacterial meningitis, prior antibiotic therapy > 24 hours, stridor, heart disease and allergy to any of the study drugs were excluded. They were randomly allocated to two groups--Group A and Group B. Group A received C. pen and gentamicin intravenously (IV), followed by oral amoxicillin and group B got amox-clav IV, followed by oral amox-clav. Minimum duration of IV therapy was 3 days and total 7 days. Respiratory rate, oxygen saturation and chest wall indrawing were monitored 6 hourly. RESULTS: 71 patients were included. There were two (5.2%) blood cultures positive in group A and three (9%) in group B. Organisms isolated were S. pneumoniae (n=3) and H. influenzae-b (n=2). There was only one treatment failure in each of the groups. One was due to penicillin resistant H. influenzae -b and the other was due to worsening of pneumonia. The mean time taken for normalization of tachypnea, hypoxia, chest wall indrawing and inability to feed was similar (P-N.S). Mean duration of IV therapy in group A was 76+/-25 hrs and group B was 75+/-24 hrs (p>0.1). CONCLUSION: In children of 2-59 months, sequential injectable C. pen and gentamicin combination, followed by oral amoxicillin or sequential IV and oral amox-clav were equally effective for the treatment of severe or very severe hypoxemic community acquired pneumonia.


Subject(s)
Administration, Oral , Amoxicillin/administration & dosage , Amoxicillin-Potassium Clavulanate Combination/therapeutic use , Anti-Bacterial Agents/therapeutic use , Child, Preschool , Drug Therapy, Combination , Female , Gentamicins/therapeutic use , Haemophilus Infections/drug therapy , Haemophilus influenzae , Humans , Infant , Infusions, Intravenous , Male , Penicillins/therapeutic use , Pneumonia, Bacterial/drug therapy , Pneumonia, Pneumococcal/drug therapy , Treatment Outcome
14.
Southeast Asian J Trop Med Public Health ; 2006 Mar; 37(2): 320-6
Article in English | IMSEAR | ID: sea-35498

ABSTRACT

To determine the prevalence, risk factors and clinical outcomes of penicillin-resistant S. pneumoniae (PRSP) in community-acquired pneumonia (CAP), a cross-sectional study was conducted between January 1995 and December 2004 at Srinagarind Hospital, Khon Kaen, Thailand. Patients hospitalized with CAP and culture proved to be S. pneumoniae were included. PRSP was found in 22 of 64 (34.4%) patients. The MIC levels of penicillin non-susceptible strains ranged between 0.25 and 0.75 microg/ml. Resistance to other antibiotics ranked: cotrimoxazole (51.6%), tetracycline (26.6%), erythromycin (20.6%), lincomycin (18.7%), chloramphenicol (12.5%) and ampicillin (1.6%). None of the isolates was resistant to cephalothin. The significant risk factors for PRSP infection were previous antibiotic use within 3 months (Adjusted OR 40.83, 95% CI 3.71 to 449.41) and alcoholism (Adjusted OR 8.82, 95% 1.25 to 62.46). Bacteremia and empyema thoracis were found more commonly in PRSP than PSSP infection, but not statistically significant. Pneumonia-related mortality was nearly the same, PRSP 9.1% vs PSSP 9.5% (p = 0.96). The reason why the clinical outcomes of these two groups were not different may be the patients were infected with mildly resistant organisms. Thus, pneumonia caused by intermediate-level penicillin resistant S. pneumoniae appears to be adequately treated with beta-lactams or aminopenicillin antibiotics. The MIC levels of penicillin resistance should be monitored further. The need for antibiotics active against drug-resistant S. pneumoniae was required if high-level penicillin resistance was detected.


Subject(s)
Adolescent , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , Community-Acquired Infections/drug therapy , Cross-Sectional Studies , Drug Resistance, Multiple, Bacterial , Female , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Penicillin Resistance , Pneumonia, Pneumococcal/drug therapy , Risk Factors , Streptococcus pneumoniae/drug effects , Thailand/epidemiology , Treatment Outcome
17.
Rev. méd. Chile ; 131(5): 505-514, mayo 2003.
Article in Spanish | LILACS | ID: lil-356110

ABSTRACT

BACKGROUND: S pneumoniae is the most common cause of community-acquired pneumonia. AIM: To evaluate the clinical characteristics, antibiotic resistance, management and prognostic factors in pneumococcal pneumonia. METHODS: Prospective evaluation in 46 adults (age +/- sd: 68 +/- 17 years) hospitalized with pneumococcal pneumonia confirmed by sputum, blood or pleural fluid cultures. Clinical and radiographic variables, risk factors for antibiotic resistance, and hospital mortality rate were recorded. RESULTS: Heart disease (39 per cent), COPD/asthma (25 per cent), and diabetes mellitus (18 per cent) were the most frequent underlying diseases. None of the patients had previously received pneumococcal vaccine. Only 17 per cent of the patients had the classic triad of chills, fever and productive cough. At admission, interestingly, 17 per cent presented with congestive heart failure. Resistance of pneumococci to penicillin, cefotaxime or erythromycin was 15 per cent, 6 per cent and 11 per cent, respectively. Antibiotic use prior to admission was significantly associated with antibiotic resistance (OR = 6; CI 95 per cent = 1.1-32; p < 0.05). Fifty per cent of the patients were admitted to intermediate or intensive care units, 15 per cent were mechanically ventilated, 20 per cent developed septic shock, 20 per cent developed acute renal failure and 13 per cent died in the hospital. Clinical factors significantly associated with higher mortality were systolic hypotension (< or = 90 mmHg), ICU admission and BUN > 30 mg per dL. CONCLUSIONS: Our data suggest that pneumococcal pneumonia is still a severe infection with high mortality; hence, efforts should be made at prevention using pneumococcal immunization.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Hospital Mortality , Pneumonia, Pneumococcal/mortality , Drug Resistance, Bacterial , Survival Analysis , Chile/epidemiology , Comorbidity , Prospective Studies , Risk Factors , Immunocompromised Host , Community-Acquired Infections/complications , Community-Acquired Infections/drug therapy , Community-Acquired Infections/mortality , Pneumonia, Pneumococcal/complications , Pneumonia, Pneumococcal/drug therapy , Prognosis , Penicillin Resistance , Intensive Care Units
18.
Rev. méd. Chile ; 130(6): 677-680, jun. 2002. tab, graf
Article in Spanish | LILACS | ID: lil-317501

ABSTRACT

Hemolytic-uremic syndrome (HUS) is an uncommon complication of pneumococcal infection. Highly suggesting findings in a patient with Streptococcus pneumoniae infection are: microangyopatic hemolytic anemia, thrombocytopenia and acute renal failure. We report a 41 years old woman, admitted to the hospital due to a severe pneumonia, that required the surgical drainage of an empyema. On admission, a drop in packed red cell volume from 41 to 25 percent, the presence of schistocytes in the blood smear, an elevation of LDH to 1,700 IU/L, a fall in haptoglobin to 5.8 mg/dL and a thrombocytopenia of 72,000 per mm3 were detected. These alterations coincided with an oliguric acute renal failure. She was treated with hemodialysis and the hemolytic syndrome was managed with plasmapheresis. She was discharged 35 days after admission and in the follow up, after 2.5 months, her serum creatinine is 1.2 mg/dL and her packed red cell volume is 41 percent


Subject(s)
Humans , Adult , Female , Streptococcus pneumoniae , Pneumonia, Pneumococcal/complications , Pleuropneumonia/complications , Hemolytic-Uremic Syndrome/etiology , Streptococcus pneumoniae , Renal Insufficiency , Renal Dialysis , Pneumonia, Pneumococcal/drug therapy , Plasmapheresis , Pleuropneumonia/drug therapy , Hemolytic-Uremic Syndrome/therapy
20.
Rev. chil. infectol ; 17(1): 39-44, 2000. tab
Article in Spanish | LILACS | ID: lil-263521

ABSTRACT

Streptococcus pneumoniae constituye un problema epidemiológico mundial por el aumento de su incidencia y aparición de cepas resistentes a los antimicrobianos considerados útiles en su manejo, como son penicilina y cefalosporinas de espectro expandido. Se presenta la revisión de 141 casos de infecciones invasoras por S. pneumoniae en un hospital pediátrico de la Región Metropolitana de Santiago, ocurridos en un período de 7 años. Destacan como formas de presentación más frecuentes meningitis (39 por ciento) y neumonía (36,9 por ciento), con una letalidad global de 6,4 por ciento. De las cepas identificadas, 23,4 por ciento presentaban resistencia a penicilina y 6,7 por ciento a cefotaxima, habiendo sido aisladas de todas las localizaciones. Se discute el tratamiento antibiótico a usar en las infecciones por cepas resistentes, siendo necesario diferenciar infección meníngea de otras infecciones sistémicas, pues el enfrentamiento terapéutico es distinto. Esto pone en evidencia la necesidad de mantener estricta vigilancia de la sensibilidad de S. pneumoniae, con el objeto de decidir el tratamiento más adecuado en cada caso


Subject(s)
Humans , Infant, Newborn , Male , Female , Infant , Child, Preschool , Meningitis, Pneumococcal/drug therapy , Pneumonia, Pneumococcal/drug therapy , Streptococcus pneumoniae/pathogenicity , Age Factors , Cefotaxime/pharmacology , Drug Resistance, Microbial , Pneumococcal Infections/etiology , Pneumococcal Infections/drug therapy , Penicillins/pharmacology , Streptococcus pneumoniae/drug effects , Streptococcus pneumoniae/isolation & purification
SELECTION OF CITATIONS
SEARCH DETAIL